WCA
MTNB icon

Windsor Creek Advisors’s Matinas BioPharma MTNB Stock Holding History

Windsor Creek Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-294
Closed -$33 – 196
2019
Q4 		$33 Buy
+294
New +$17K 0.01% 133

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Windsor Creek Advisors's MTNB Position: Q1 2020 in Review

Windsor Creek Advisors sold out of Matinas BioPharma (MTNB) in Q1 2020, closing a stake of 294 shares — an estimated $33 sold.

Windsor Creek Advisors first reported a position in MTNB in Q4 2019 and held it in 1 quarter. The position peaked at $33 in Q4 2019. 68 funds tracked by Wall St. Rank hold MTNB as of Q1 2020.

  • Windsor Creek Advisors reported no remaining Matinas BioPharma position as of Q1 2020 after selling out during the quarter.
  • Windsor Creek Advisors sold 294 Matinas BioPharma shares in Q1 2020, an estimated $33.
  • Windsor Creek Advisors first reported a position in Matinas BioPharma in Q4 2019 and held it in 1 quarter.
  • Windsor Creek Advisors's Matinas BioPharma position peaked at $33 in Q4 2019.
  • 68 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2020.

Based on Windsor Creek Advisors's 13F filing for Q1 2020, filed 12 May 2020.